Stage II Ovarian Cancer: Dana's Survivor Story

Patient Info: Dana McKay | Stage II

After surgery and 6 rounds of carboplatin and paclitaxel, she described herself as cancer-free in February 2019.

MD AndersonRead more →

Stage I Ovarian Cancer: Jane's Survivor Story

Patient Info: Jane McGrath, female, 40s | Stage I

Jane was in remission after surgery and 6 rounds of chemotherapy and later became an ovarian-cancer volunteer and advocate.

Memorial Sloan KetteringRead more →

Stage IV Ovarian Cancer: Manisha's Survivor Story

Patient Info: Manisha Koirala, Female | Stage IV

She was declared cancer-free after her final chemotherapy cycle on April 30, 2013, and remained in remission more than 6 years later.

Memorial Sloan KetteringRead more →

Stage II Ovarian Cancer: Elizabeth's Survivor Story

Patient Info: Elizabeth Jardinella, Female, Under 40 | Stage II

Cancer-free for about 2 years, with surveillance scans continuing to show no evidence of disease while she takes maintenance letrozole.

MD AndersonRead more →

Early-stage ovarian squamous cell carcinoma arising in a mature cystic teratoma

Patient Info: Anonymized, female, 50s | Stage I

Biomarkers: ovarian tumor HPV DNA-negative; p16-negative

She achieved complete remission and had no evidence of recurrence 24 months after surgery, at follow-up in June 2026.

PubMed CentralRead more →

Stage II Ovarian Squamous Cell Carcinoma: Caitlin's Survivor Story

Patient Info: Caitlin Koehler, female, Under 40 | Stage II

Biomarkers: PD-L1: high expression

After surgery for recurrence, Caitlin remained on maintenance therapy and her follow-up scans showed no evidence of disease.

MD AndersonRead more →

Stage IV Ovarian Cancer First Found Through an Umbilical Metastasis

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: WT1-positive; CK7-positive; CA-125 321 U/mL at diagnosis

Metastatic Site: umbilicus

After 9 months of bevacizumab maintenance, her clinical and imaging findings remained stable.

PubMed CentralRead more →

Eight years cancer-free after treatment for a rare ovarian Brenner tumor

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: High Ki-67

At 8-year follow-up, surveillance showed no clinical or radiologic evidence of disease.

PubMed CentralRead more →

Durable response after multiple treatments for ovarian clear cell cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HRD-positive; BRCA-negative; ARID1A mutation; PD-L1 CPS 30

She achieved a complete response, completed maintenance immunotherapy in May 2024, and continued anlotinib with normal follow-up imaging and tumor markers.

PubMed CentralRead more →

Ovarian Cancer Remission Before Zolpidem Withdrawal Delirium

Patient Info: Anonymized, female

The ovarian cancer had not recurred for about 6 years, and she remained in remission.

PubMed CentralRead more →

Ovarian Cancer Metastatic to an Axillary Lymph Node Without Breast Disease

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1/2 negative

Metastatic Site: right axillary lymph node

Secondary cytoreductive surgery in April 2025 achieved complete macroscopic cytoreduction, and she was discharged without complications.

PubMed CentralRead more →

Ovarian Cancer Remission With Olaparib After Chemotherapy Intolerance

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: germline BRCA1 mutation

At 48 months, imaging showed complete remission and CA125 was normal while she continued reduced-dose olaparib.

PubMed CentralRead more →

Advanced high-grade serous ovarian cancer with treatment-resistant progression and hyperprolactinemia

Patient Info: Anonymized, Female, 50s

Biomarkers: BRCA1 variant of uncertain significance

The ovarian cancer continued to progress despite multiple treatments, and she died 2.5 years after the ovarian-cancer diagnosis.

PubMed CentralRead more →

Small Cell Ovarian Cancer Causing Acute Kidney Injury

Patient Info: Anonymized, Female | Stage III

Biomarkers: Somatic SMARCA4 alterations; no germline SMARCA4 pathogenic variant

Combined pembrolizumab, carboplatin, and paclitaxel was continued after marked radiologic improvement, with an excellent PET-CT response documented after 13 cycles.

PubMed CentralRead more →

Ovarian Cancer Spreads to the Breast During Platinum-Resistant Recurrence

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1/2-negative; HRD-positive; PD-L1-positive; folate receptor alpha-positive

Metastatic Site: right breast, right axillary lymph nodes, cervical…

She remained alive with stable disease about 2 years after the breast metastasis was diagnosed while receiving seventh-line mirvetuximab-soravtansine.

PubMed CentralRead more →

BRCA1-Mutated Ovarian Cancer Responding to Niraparib After Olaparib Progression

Patient Info: Anonymized, Female, 60s

Biomarkers: Germline BRCA1 pathogenic variant c.188T>A; CA-125 4

Two months after starting niraparib, imaging showed a partial response and CA-125 normalized. At 15 months, she had achieved a complete response and remained progression-free while niraparib continued.

PubMed CentralRead more →

Ovarian cancer chemotherapy continued after paclitaxel-related liver injury

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: somatic BRCA1/2 negative

She completed all 6 planned chemotherapy cycles after dose reduction for liver toxicity and then entered routine surveillance.

PubMed CentralRead more →

Metastatic Ovarian Cancer Presenting With Painful Finger Ischemia

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Biomarkers: CA-125: 90.6 kU/L after 4 cycles of chemotherapy

Metastatic Site: peritoneum|omentum

She continued chemotherapy and palliative symptom management after debulking surgery. She died from an intracranial hemorrhage 10 months after her original presentation.

PubMed CentralRead more →

Stage III Ovarian Cancer: Jaclyn's Patient Story

Patient Info: Jaclyn (Jackie) VanRaaphorst | Stage III

Biomarkers: FRα-positive; CA-125 monitored

AACR later reported that Jackie died on January 16, 2025.

Ovarian Cancer: Jennifer's Patient Story

Patient Info: Jennifer Thorn, Female, 40s

Living with ovarian cancer and continuing gemcitabine after about 2 years of treatment.

Dana-FarberRead more →

Stage I BRCA1 Ovarian Cancer: Carol's Survivor Story

Patient Info: Carol Arnhart | Stage I

Biomarkers: BRCA1 mutation

After staging surgery and 6 rounds of carboplatin and paclitaxel, she reported no evidence of ovarian cancer.

MD AndersonRead more →

Stage IV Ovarian Cancer Complicated by Anti-Yo Cerebellar Degeneration

Patient Info: Anonymized, Female | Stage IV

Biomarkers: CA-125: 1767 kU/L; anti-Yo antibodies positive in serum and cerebrospinal fluid

Her anti-Yo paraneoplastic cerebellar degeneration progressed despite methylprednisolone and plasma exchange. Care became palliative, and she died 2 months after hospital admission.

PubMed CentralRead more →

Stage IIIC Ovarian Cancer Found During Preoperative Screening

Patient Info: Anonymized, Female | Stage III

Biomarkers: BRCA1 pathogenic variant on homologous recombination deficiency testing; germline BRCA1 pathogenic variant

At approximately 1 year after surgery, she was alive without evidence of recurrence while continuing olaparib and bevacizumab maintenance therapy.

PubMed CentralRead more →

Recurrent Malignant Ovarian Steroid Cell Tumor Treated With Multiple Therapies

Patient Info: Anonymized, Female

Biomarkers: PIK3CA, and ATM mutations; ER negative; PR negative

She experienced repeated pelvic and lung recurrences. Platinum-based treatment produced a complete PET-CT response and olaparib maintenance provided about 1 year without progression before a 5 mm lung recurrence was surgically removed.

PubMed CentralRead more →